Conivaptan: a step forward in the treatment of hyponatremia?

References

• AdroguéHJMadiasNEHyponatremiaN Engl J Med20003421581910824078
   PubMed Web of Science ®Google Scholar
• AndreoliTEWater: Normal balance, hyponatremia, and hypernatremiaRen Fail2000227113511104160
   PubMed Web of Science ®Google Scholar
• ArieffAILlachFMassrySGNeurological manifestations and morbidity of hyponatremia: Correlation with brain water and electrolytesMedicine (Baltimore)19765512191256311
   PubMed Web of Science ®Google Scholar
• Astellas Pharma US, IncVaprisol (conivaptan hydrochloride injection) product monograph2007Deerfield, IL
   Google Scholar
• BartterFCSchwartzWBThe syndrome of inappropriate secretion of antidiuretic hormoneAm J Med1967427908065337379
   PubMed Web of Science ®Google Scholar
• BaylisPHRegulation of vasopressin secretionBaillieres Clin Endocrinol Metab19893313302698140
   PubMed Web of Science ®Google Scholar
• BaylisPHThe syndrome of inappropriate antidiuretic hormone secretionInt J Biochem Cell Biol2003351495912824060
   PubMed Web of Science ®Google Scholar
• BennaniSLAbouqalRZeggwaghAAIncidence, causes and prognostic factors of hyponatremia in intensive careRev Med Interne200324224912706778
   PubMed Web of Science ®Google Scholar
• BerlTTreatment of the syndrome of inappropriate antidiuretic hormone secretion and the emergence of vasopressin antagonists for hyponatremic disorders2007May 2007 [online] URL: http://www.nephrologyrounds.org
   Google Scholar
• BernierVMorelloJPZarrukAPharmacologic Chaperones as a Potential Treatment for X-Linked Nephrogenic Diabetes InsipidusJ Am Soc Nephrol2006172324316319185
   PubMed Web of Science ®Google Scholar
• BorroniGMaggiASangiovanniAClinical relevance of hyponatraemia for the hospital outcome of cirrhotic patientsDig Liver Dis2000326051011142560
   PubMedGoogle Scholar
• BurnierMFrickerAFHayozDPharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjectsEur J Clin Pharmacol199955633710638391
   PubMed Web of Science ®Google Scholar
• CardenasAArroyoVMechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascitesBest Pract Res Clin Endocrinol Metab2003176072214687592
   PubMed Web of Science ®Google Scholar
• DavisonJMVallottonMBLindheimerMDPlasma osmolality and urinary concentration and dilution during and after pregnancy: Evidence that lateral recumbency inhibits maximal urinary concentrating abilityBr J Obstet Gynaecol19818847297236550
   PubMedGoogle Scholar
• DeVitaMVGardenswartzMHKoneckyAIncidence and etiology of hyponatremia in an intensive care unitClin Nephrol19903416362257702
   PubMed Web of Science ®Google Scholar
• DunnFLBrennanTJNelsonAEThe role of blood osmolality and volume in regulating vasopressin secretion in the ratJ Clin Invest197352321294750450
   PubMed Web of Science ®Google Scholar
• FraserCLArieffAIEpidemiology, pathophysiology, and management of hyponatremic encephalopathyAm J Med199710267779209203
   PubMed Web of Science ®Google Scholar
• FriedLFPalevskyPMHyponatremia and hypernatremiaMed Clin North Am1997815856099167647
   PubMed Web of Science ®Google Scholar
• FujiwaraTMBichetDGMolecular biology of hereditary diabetes insipidusJ Am Soc Nephrol20051628364616093448
   PubMed Web of Science ®Google Scholar
• GattoneVHWangXHarrisPCInhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonistNat Med200391323614502283
   PubMed Web of Science ®Google Scholar
• GerbesALGulbergVGinesPTherapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: Arandomized double-blind multicenter trialGastroenterology2003124933912671890
   PubMed Web of Science ®Google Scholar
• GhaliJKKorenMJTaylorJFEfficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremiaJ Clin Endocrinol Metab20069121455216522696
   PubMed Web of Science ®Google Scholar
• GhaliJKSmithNEfficacy of the vasopressin V1A/V2 antagonist conivaptan in patients with euvolemic or hypervolemic hyponatremiaJ Am Soc Nephrol200415355A abstr SA-P0251
   Google Scholar
• GheorghiadeMGattisWAO’ConnorCMEffects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trialJAMA200429119637115113814
   PubMed Web of Science ®Google Scholar
• GheorghiadeMNiaziIOuyangJVasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trialCirculation20031072690612742979
   PubMed Web of Science ®Google Scholar
• GoldbergAHammermanHPetcherskiSPrognostic importance of hyponatremia in acute ST-elevation myocardial infarctionAm J Med2004117242815308433
   PubMed Web of Science ®Google Scholar
• GrossPBisahaJGSmithNConivaptan, a novel V1A and V2 antagonist, increased serum sodium and effective water clearance in patients with euvolemic or hypervolemic hyponatremiaJ Am Soc Nephrol200415355A abstr SA-P0243
   Google Scholar
• Hew-ButlerTAlmondCAyusCExercise-Associated Hyponatremia (EAH) Consensus PanelClin J Sport Med2005152081316003032
   PubMed Web of Science ®Google Scholar
• IshikawaSESchrierRWPathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretionClin Endocrinol200358117
   PubMed Web of Science ®Google Scholar
• LandwehrMHulingUStudy shows vaprisol® is effective in increasing serum sodium levels and well-tolerated in patients with euvolemic or hypervolemic hyponatremia2007 Astella News Release, http://www.astellas.us/press_room/docs
   Google Scholar
• LeeCRWatkinsMLPattersonJHVasopressin: A new target for the treatment of heart failureAm Heart J200314691812851603
   PubMed Web of Science ®Google Scholar
• LeeCTGuoHRChenJBHyponatremia in the emergency departmentAm J Emerg Med200018264810830680
   PubMed Web of Science ®Google Scholar
• MarkowitzGSRadhakrishnanJKambhamNLithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathyJ Am Soc Nephrol20001114394810906157
   PubMed Web of Science ®Google Scholar
• MillerPDLinasSLSchrierRWPlasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patientsJAMA1980243251356770106
   PubMed Web of Science ®Google Scholar
• PhamPCPhamPMPhamPTVasopressin excess and hyponatremiaAm J Kidney Dis2006477273716632011
   PubMed Web of Science ®Google Scholar
• RobbenJHKnoersNVDeenPMCell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidusAm J Physiol Renal Physiol2006291F2577016825342
   PubMed Web of Science ®Google Scholar
• RobertsonGLPhysiology of ADH secretionKidney Int, Suppl198721S2063476800
   PubMed Web of Science ®Google Scholar
• RobinsonAGRobertsMMEvronWAHyponatremia in rats induces downregulation of vasopressin synthesisJ Clin Invest199086102392211999
   PubMed Web of Science ®Google Scholar
• RouleauJ-LPackerMMoyeLPrognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captoprilJ Am Coll Cardiol199424583917915733
   PubMed Web of Science ®Google Scholar
• RufAEKremersWKChavezLLAddition of serum sodium into the MELD score predicts waiting list mortality better than MELD aloneLiver Transpl2005113364315719386
   PubMed Web of Science ®Google Scholar
• SedlacekMSchoolwerthACRemillardBDElectrolyte disturbances in the intensive care unitSemin Dial20061949650117150050
   PubMed Web of Science ®Google Scholar
• SerradeilLe GalCWagnonJValetteGNonpeptide vasopressin receptor antagonists: Development of selective and orally active V1A, V2 and V1B receptor ligandsProg Brain Res200213919721012436936
   PubMed Web of Science ®Google Scholar
• SingerIRotenbergDDemeclocycline-induced nephrogenic disbetes insipidus. In vivo and in vitro studiesAnn Intern Med197379679834356453
   PubMed Web of Science ®Google Scholar
• SladekCDRegulation of vasopressin release by neurotransmitters, neuropeptides and osmotic stimuliProg Brain Res19836071906198689
   PubMed Web of Science ®Google Scholar
• SoupartAGrossPLegrosJ-JSuccessful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2- receptor antagonistClin J Am Soc Nephrol2006111546017699341
   PubMed Web of Science ®Google Scholar
• TerzianCFryeEBPiotrowskiZHAdmission hyponatremia in the elderly: Factors influencing prognosisJ Gen Intern Med1994989918164083
   PubMed Web of Science ®Google Scholar
• ThibonnierMColesPThibonnierAThe basic and clinical pharmacology of nonpeptide vasopressin receptor antagonistsAnnu Rev Pharmacol Toxicol20014117520211264455
   PubMed Web of Science ®Google Scholar
• TorresVEHarrisPCMechanisms of Disease: autosomal dominant and recessive polycystic kidney diseasesNat Clin Pract Nephrol20062405516932388
   PubMedGoogle Scholar
• TorresVEWangXQianQEffective treatment of an orthologous model of autosomal dominant polycystic kidney diseaseNat Med200410363414991049
   PubMed Web of Science ®Google Scholar
• UdelsonJESmithWBHendrixGHAcute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failureCirculation200110424172311705818
   PubMed Web of Science ®Google Scholar
• VerbalisJGBisahaJGSmithNNovel vasopressin V1A and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremiaJ Am Soc Nephrol200415356A abstr SA-P0254
   Google Scholar
• VerbalisJGDisorders of body water homeostasisBest Pract Res Clin Endocrinol Metab20031747150314687585
   PubMed Web of Science ®Google Scholar
• [VHA] VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory PanelNational PBM Drug Monograph: Conivaptan Hydrochloride Injection (Vaprisol®)2006
   Google Scholar
• WongFBleiATBlendisLMA vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trialHepatology2003371829112500203
   PubMed Web of Science ®Google Scholar
• ZerbeRStropesLRobertsonGVasopressin function in the syndrome of inappropriate antidiuresisAnnu Rev Med198031315276772090
   PubMed Web of Science ®Google Scholar